• PN: B116665


45x Ab-conjugated beads (S4P9 - Human PAPP-A Ab-bead). PN: B116665A. One vial containing 100 µL of anti-Human PAPP-A conjugated to AimPlex Bead S4P9.

25x Biotin-detection (PAPP-A Biotin-dAb). PN: B116665B. One vial containing 100 µL of biotinylated anti-Human PAPP-A.

Lyophilized Standard Mix-Human Group 8, Panel B, 11-Plex. PN: HG82011. One vial containing lyophilized recombinant Cystatin C, FGF-1, FGF-19, Flt-3L, GDF-15, Granzyme B, NGAL, PAPP-A, SLPI, RAGE, and ST2.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human Human PAPP-A. Can be multiplexed with other analytes in Human Group 8.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 20 pg/mL

Quantitation range:

LLOQ: < 40 pg/mL

ULOQ: > 20,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 8: Negligible

Sample volume: 15 µL/test


Pappalysin-1 also known as pregnancy-associated plasma protein A (PAPPA) is used in screening tests for Down syndrome. PAPPA is thought to be involved in local proliferative processes such as wound healing and bone remodeling. Low plasma level of this protein has been suggested as a biochemical marker for pregnancies with aneuploid fetuses. Low PAPPA may be seen in prenatal screening for Down syndrome. Low levels may alternatively predict issues with the placenta, resulting in adverse complications such as intrauterine growth restriction, preeclampsia, placental abruption, premature birth, or fetal death. Diseases associated with PAPPA include tricuspid valve insufficiency and triploidy.


1.      Breathnach FM, Malone FD (2007). "Screening for aneuploidy in first and second trimesters: is there an optimal paradigm?". Curr. Opin. Obstet. Gynecol. 19 (2): 176–82. doi:10.1097/GCO.0b013e3280895e00. PMID 17353686.

2.      Overgaard MT, Haaning J, Boldt HB, Olsen IM, Laursen LS, Christiansen M, Gleich GJ, Sottrup-Jensen L, Conover CA, Oxvig C (October 2000). "Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor". J. Biol. Chem. 275 (40): 31128–33. doi:10.1074/jbc.M001384200. PMID 10913121.

3.      Overgaard MT, Sorensen ES, Stachowiak D, Boldt HB, Kristensen L, Sottrup-Jensen L, Oxvig C (January 2003). "Complex of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein. Disulfide structure and carbohydrate attachment". J. Biol. Chem. 278 (4): 2106–17. doi:10.1074/jbc.M208777200. PMID 12421832.

4.      Oxvig C, Sand O, Kristensen T, Gleich GJ, Sottrup-Jensen L (June 1993). "Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein". J. Biol. Chem. 268 (17): 12243–6. PMID 7685339.